Prevention and treatment of Respiratory Distress Syndrome [RDS] in premature infants.
For intratracheal use only. Prevention: In premature infants ≤ 1.25gm administer as soon as possible, preferably within 15mins of birth. Rescue: give as soon as possible, preferably by 8 hrs of age. The dose depends on weight and it ranges between 2.6mL to 8.0mL.
Mode of action
Brands containing this Ingredient
Drug Index 2.0 is hereOur new update features a more powerful search feature and easier login.
issues? Contact us
today. Contact Us
Mode of Action
A natural bovine lung extract to which colfosceril palmitate, palmitic acid and tripalmitin are added to mimic the natural lung surfactant. Pulmonary surfactant lowers surface tension on alveolar surfaces during respiration and stabilizes the alveoli against collapse at resting transpulmonary pressures.
It must be administered by clinicians experienced with intubation, ventilator management and general care of premature infants.
None is currently known
Transient bradycardia, oxygen desaturation; increased risk for sepsis.
Drug interactions: None is currently known.
Side effects: Transient bradycardia, oxygen desaturation; increased risk for sepsis.